|
 Raptor's shares were up 9 percent at $16.24 in
premarket trading on Thursday.
The drug slowed the progression of muscle spasms, eye and hand
movements and loss of balance compared to a placebo.
The trial enrolled 96 patients with Huntington's disease, a genetic
disorder caused by the degeneration of nerve cells in parts of the
brain, resulting in the loss of executive function and
uncontrollable movements.
The company said seven patients discontinued treatment during the
study. Six of them were treated with the drug, codenamed RP103.
Raptor is also testing the drug in a mid-stage study for
non-alcoholic fatty liver disease in children.
(Reporting by Vrinda Manocha in
Bangalore; editing by Maju Samuel)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
